$IVST Call Center Contract Billings With Fortune 500

New Post Public Reply Private Reply Replies (0) Message Board
SpotlightGrowth1
270
$IVST Call Center Contract Billings With Fortune 500 Company to Exceed $1 Million Over First Twelve Months

Sacramento, CA., May 24, 2018 (GLOBE NEWSWIRE) -- A new update has been published on Innovest Global, Inc. (OTC PINK: IVST). Innovest Global, Inc. is a diversified holding company that focuses on acquiring niche, high-growth businesses that are capable of generating significant annual revenue. The company’s planned subsidiaries operate across telehealth, biotech, commercial energy, business-to-business distribution, national call center and auto sales.

Global Lighting as a Service Market Estimated To Reach $4.74 Billion By 2025: Research and Markets

Going “green” has been a big theme over the past several years. Aging infrastructure and energy systems continue to be incredibly inefficient and cost prohibitive. In addition, growing awareness of global climate change has had an impact on the energy efficiency market. As social awareness, cost savings, and government incentives continue to take hold in the energy efficiency markets, market research firms see a bright future ahead.

According to ResearchAndMarkets, the global lighting as a service (LaaS) market is forecast to be worth $4.74 billion by 2025. The LaaS market was developed as a new financial structure to combat the potentially high upfront costs associated with installation. The LaaS model allows private and public entities to continue capitalizing on the latest innovations and developments with the LED lighting industry.

In PwC’s “2017 Power and Utilities Trend” report, analysts concluded that a vast majority of the growth will come from a “blueprint for a service-based model.” This includes: emerging technologies, monitoring equipment, sensors, energy management technology, etc.

According to Technavio market research, the global industrial energy efficiency services market is forecast to be valued around $10.18 billion by 2020, which represents a compound annual growth rate (CAGR) of 6%.

Innovest Global: Call Center Lands Major Exclusive Contract With Fortune 500 Company

Innovest Global recently announced that its call center subsidiary, Crestwood Management, has won a $650,000 exclusive contract with a Fortune 500 company that is generating annual revenues over $2 billion. Over the first twelve months of the exclusive contract, the call center subsidiary is slated to receive over $1 million in billings for services rendered.

The latest contract marks “the single largest contract for Innovest, since launching the Commercial & Industrial Division six months ago.”

“Given the quality of the companies we were bidding against, we’re extremely proud of this accomplishment,” said Sally Emch, President of Innovest Call Center Operations, who led the bid process for Innovest. “It’s a great validation of our call center to win a major bid from a Fortune 500 company, and also of the Innovest business model as a whole. I’m so excited by our sales growth and that we are officially ‘on the map,’ and winning major national projects.”

This comes as the company just recently learned that its endeavors are beginning to attract attention from some major investors. During the first quarter 2018, a 13F filing shows that Ohio-based, Winslow Asset Management, initiated a new position in Innovest Global. According to the data, the asset management firm purchased 10,000 shares at prices between $0.01 and $0.44, with the average price estimated to be around $0.13.

Innovest Global was the only new position made by Winslow Asset Management during the first quarter, which also added to its other positions such as Amgen and Berkshire Hathaway. Overall, Winslow Asset Management holds 88 stocks with a total value of $516 million, as of March 31, 2018.

For more information on Innovest Global, Inc., please visit http://innovestglobal.com and http://spotlightgrowth.com/index.php/2018/05/...0-company/

SpotlightGrowth.com is a digital hub for micro-caps, small-caps, crowdfunding, cryptocurrency, and other emerging growth investors. SpotlightGrowth.com serves as our media subsidiary and provides insights on small cap companies.

Disclaimer:

Spotlight Growth is compensated, either directly or via a third party, to provide investor relations services for its clients. Spotlight Growth creates exposure for companies through a customized marketing strategy, including design of promotional material, the drafting and editing of press releases and media placement.

All information on featured companies is provided by the companies profiled, or is available from public sources. Spotlight Growth and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on external sources that Spotlight Growth believes to be reliable, but its accuracy is not guaranteed. Spotlight Growth may create reports and content that has been compensated by a company or third-parties, or for purposes of self-marketing. Spotlight Growth was compensated two thousand five hundred dollars cash and fifty thousand restricted shares for the creation and dissemination of this content.

This material does not represent an investment solicitation. Certain statements contained herein constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements with respect to the Company’s plans and objectives, projections, expectations and intentions. These forward-looking statements are based on current expectations, estimates and projections about the Company’s industry, management’s beliefs and certain assumptions made by management.

The above communication, the attachments and external Internet links provided are intended for informational purposes only and are not to be interpreted by the recipient as a solicitation to participate in securities offerings. Investments referenced may not be suitable for all investors and may not be permissible in certain jurisdictions.

Spotlight Growth and its affiliates, officers, directors, and employees may have bought or sold or may buy or sell shares in the companies discussed herein, which may be acquired prior, during or after the publication of these marketing materials. Spotlight Growth, its affiliates, officers, directors, and employees may sell the stock of said companies at any time and may profit in the event those shares rise in value. For more information on our disclosures, please visit: http://spotlightgrowth.com/index.php/disclosures/

Innovest Global, Inc. (IVST) Stock Research Links

IVST Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 43

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 47

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 38

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 44

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 38

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 35

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation Launched into AppLovin Corporation's Alleged Fraud

Updated Category News Views 386

Investigation into AppLovin Corporation In recent news, a substantial class action lawsuit has emerged against AppLovin Corporation (NASDAQ: APP). This national law firm, known for advocating for investors, aims to hold the company accountable for alleged securities law violations. Understanding the Class Action Lawsuit This lawsuit pertains to any individuals or entities...

Continue Reading
Safe Harbor Financial Expands Support for Cannabis Operators

Updated Category News Views 33

Safe Harbor Financial Takes Bold Step in Cannabis Financing In a remarkable move, Safe Harbor Financial has successfully arranged a secured credit facility valued at $1.07 million. This milestone supports a cannabis operator, marking a significant step in bolstering financial services within the cannabis industry. With their expertise in facilitating innovative financial...

Continue Reading
Nidec Corporation Faces Securities Investigation: Key Insights

Updated Category News Views 224

Understanding Nidec Corporation's Current Challenges Nidec Corporation is undergoing scrutiny due to serious allegations in its business practices. This Japanese manufacturer, known for its electronic components, faces potential claims of issuing misleading information to its investors. Recent developments have raised questions about its transparency and accountability in...

Continue Reading
Understanding HCI Group's Short Interest Trends and Insights

Updated Category News Views 126

An Overview of HCI Group's Short Interest HCI Group's short interest has sparked interest among traders and investors alike, showing a recent increase of 7.38% from the previous report. This shift indicates that there are currently around 404 thousand shares sold short, comprising 4.95% of the company’s total tradable shares. Observing the trading volume, it has been...

Continue Reading
Fresenius Kabi Introduces New Epinephrine Injection for Patients

Updated Category News Views 151

Fresenius Kabi Launches Epinephrine Injection, USP Fresenius Kabi, a proud branch of the Fresenius organization, has taken a significant step in enhancing its pharmaceutical portfolio in the United States by making available Epinephrine Injection, USP. This launch positions Fresenius Kabi at the forefront as it becomes the first company to offer a generic 1mg/1mL vial of...

Continue Reading